Effects of GSK v Teva Ripple after SCOTUS Denies Cert
May 23, 2023
Chad Landmon, Ross Blau, and Gulrukh Haroon
Life Sciences IP Review
Axinn partner Chad Landmon and associates Ross Blau and Gulrukh Haroon co-authored the Life Sciences IP Review article, "Effects of GSK v Teva Ripple after SCOTUS Denies Cert."
Click here to access the publication. A subscription is required.